Suicidal ideation

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

Retrieved on: 
Monday, March 11, 2024

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS). These data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS).
  • These data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time.
  • “The magnitude and depth of responses for signs and symptoms of Hidradenitis Suppurativa in this long-term study are consistent with izokibep’s mechanism of action.
  • A confirmatory phase 3 trial of approximately 400 patients is planned to address guidance on size of safety database given the FDA no longer considers moderate-to-severe HS an orphan disease.

Six Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health Care

Retrieved on: 
Friday, February 23, 2024

The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.

Key Points: 
  • The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.
  • Kate NeuroPsych represents a groundbreaking approach to mental health care — offering 24/7 availability, personalized recommendations, and worldwide access — being designed by scientific leaders who are positively disrupting healthcare delivery at Revitalist and Sama Therapeutics .
  • Looking ahead, Kathryn envisions a future where psychedelics are normalized as essential tools in mental health care.
  • With each milestone she achieves, Kathryn Walker continues to redefine the boundaries of mental health care and inspire hope for a brighter, more compassionate future.

Brightside Health Expands Medicaid & Medicare Access for Greater Telemental Health Coverage

Retrieved on: 
Wednesday, February 21, 2024

Brightside Health today announced new and expanded payer partnerships to support Medicaid and Medicare.

Key Points: 
  • Brightside Health today announced new and expanded payer partnerships to support Medicaid and Medicare.
  • And among the 65 million Americans enrolled in Medicare, the Centers for Medicare & Medicaid Services reported that 25% experience mental illness .
  • “No mental health platform is complete without addressing the needs of Medicaid and Medicare beneficiaries, and these partnerships will provide access to life-saving mental health care for millions more people,” said Brad Kittredge, co-founder and CEO of Brightside Health.
  • “We are scaling quickly to ensure access to high-quality, measurably better mental health treatment.

Addressing New York's Youth Mental Health Crisis, Montefiore Announces Plans for New Pediatric Inpatient Psychiatry Unit

Retrieved on: 
Wednesday, March 6, 2024

BRONX, N.Y., March 6, 2024 /PRNewswire/ -- Montefiore today announced plans for a new pediatric inpatient psychiatry unit adding a new care option to address the unmet urgent behavioral and mental health needs of children and adolescents in the Bronx. The Montefiore Einstein Center for Children's Mental Health of the Children's Hospital at Montefiore Einstein will be funded in part by a nearly $6 million appropriation to Montefiore spearheaded by New York State Assembly Speaker Carl Heastie and Assembly Member Michael Benedetto. The 21-bed child and adolescent unit will be located within the New York City Children's Center (NYCCC) campus adjacent to the Albert Einstein College of Medicine and will serve as a model for urban pediatric inpatient psychiatric services. The new program will physically and programmatically extend the capacity of CHAM to provide a full range of medical and behavioral health services for youth in the region. The proposed center will be designed to provide best-in-class intensive treatment for youth with serious behavioral health conditions including severe depression, anxiety, trauma, suicidal thoughts, psychosis and other acute psychiatric conditions.

Key Points: 
  • BRONX, N.Y., March 6, 2024 /PRNewswire/ -- Montefiore today announced plans for a new pediatric inpatient psychiatry unit adding a new care option to address the unmet urgent behavioral and mental health needs of children and adolescents in the Bronx.
  • The new program will physically and programmatically extend the capacity of CHAM to provide a full range of medical and behavioral health services for youth in the region.
  • As a leading health system in New York renowned for delivering exceptional care, I am confident that Montefiore will exceed in tackling mental health disparities with the new pediatric psychiatry unit," said New York State Assembly Speaker Carl Heastie.
  • The Montefiore pediatric psychiatry unit will provide 24/7 best-in-class care and access to comprehensive evaluation and care administered by mental health professionals expert in pediatric psychiatry.

Charlie Health and Memorial Hermann Health System Collaborate to Expand Critical Mental Health Access

Retrieved on: 
Tuesday, March 5, 2024

and HOUSTON, March 5, 2024 /PRNewswire/ -- Charlie Health, the leading provider of virtual high-acuity mental health care for young people, and Memorial Hermann Health System are collaborating to improve access to outpatient mental health treatment programs for Houstonians most at risk for crisis.

Key Points: 
  • and HOUSTON, March 5, 2024 /PRNewswire/ -- Charlie Health, the leading provider of virtual high-acuity mental health care for young people, and Memorial Hermann Health System are collaborating to improve access to outpatient mental health treatment programs for Houstonians most at risk for crisis.
  • She added, "Addressing the mental health crisis requires proactive efforts to eliminate barriers to care for those who require an additional level of mental health support, which is exactly what Memorial Hermann is doing with Charlie Health."
  • In addition to improving access to essential mental health services, Charlie Health is producing industry-leading outcomes.
  • Peer-reviewed research found that Charlie Health drives positive outcomes, with 94% of Charlie Health patients avoiding further admissions to the emergency department for mental health reasons in the three months following treatment.

NeuroFlow Publishes New Study on Efficacy of Natural Language Processing

Retrieved on: 
Thursday, February 29, 2024

PHILADELPHIA, Feb. 29, 2024 /PRNewswire-PRWeb/ -- NeuroFlow, a behavioral health technology and analytics company helping to manage and measure population risk, has published a new paper titled, "Using Natural Language Processing to Detect Suicidal Ideation and Prompt Urgent Interventions" in the journal of Innovations in Digital Health, Diagnostics, and Biomarkers. The findings shed light on the new and emerging capabilities of artificial intelligence (AI) for improving the detection of suicide risk among populations.

Key Points: 
  • NeuroFlow's technology can understand the context of language, making it a critical tool for identifying high-risk words or phrases.
  • "Our commitment to leveraging technology for mental health extends far beyond this study," NeuroFlow Chief Product Officer Julia Kastner said.
  • NeuroFlow has worked with leading researchers across the field of healthcare to validate its approach to supporting mental health care.
  • For the complete study, and access to other published work from NeuroFlow, please visit here .

Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") launches MOTPOLY XR™ (lacosamide) extended-release capsules C-V, the first, and only once-daily formulation of lacosamide

Retrieved on: 
Monday, February 26, 2024

MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

Key Points: 
  • MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
  • MOTPOLY XR is bioequivalent to Vimpat® (lacosamide) film-coated tablets, C-V and provides a new once-daily option at equivalent doses.
  • "MOTPOLY XR marks a major milestone for Aucta as our 1st branded pharmaceutical product to enter the US market.
  • To report SUSPECTED ADVERSE REACTIONS, contact Aucta Pharmaceuticals, Inc. at 1-800-655-9902 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

Retrieved on: 
Monday, February 12, 2024

TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.

Key Points: 
  • TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.
  • The Company aims to respond to satisfy the preliminary thoughts on possible deficiencies before the goal date.
  • The Company received a waiver from the FDA for bioequivalence studies and has not identified any deficiencies.
  • A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

Alberta’s new policies are not only anti-trans, they are anti-evidence

Retrieved on: 
Monday, February 5, 2024

Like other experts, we worried these policies would mimic the parental rights legislation recently introduced in Saskatchewan and New Brunswick.

Key Points: 
  • Like other experts, we worried these policies would mimic the parental rights legislation recently introduced in Saskatchewan and New Brunswick.
  • Smith has unveiled a suite of policies that directly attack trans and gender-diverse children and youth in Alberta.
  • As we explain below, these policies are at odds with research about gender-affirming care, curriculum and sports.

Evidence on trans-affirming care

  • Like all medicines, side effects are a risk but researchers caution against fear-mongering in response to gender-affirming care.
  • The evidence about trans-affirming health care for youth is clear — it saves lives.
  • Rather than restrict life-saving medical care, experts in fertility medicine call for increased accessibility for trans people to fertility services.

Sex education evidence

  • Classroom instruction on gender, sexuality and sexual orientation also now requires parental notification and opt-in.
  • Finally, third-party resource materials on gender, sexuality and sexual orientation in schools need to be pre-approved by the ministry to make sure they’re “age-appropriate.” Education experts agree that what is needed to protect youth — including cisgender and heterosexual kids — from potential abuse is robust and consent-based sexual health education.
  • Youth have the right to knowledge and skills about their bodies, consent, safe/unsafe touch and healthy relationships.

Risk of parental, peer rejection

  • This process essentially requires schools to “out” youth to their parents, who may reject their children.
  • Smith incorrectly suggests that parental rejection of 2SLGBTQIA+ kids is rare.
  • For those who experience family rejection, the rates of suicide are incredibly high.

Trans athletes evidence

  • Smith’s policy will also ban trans girls and women athletes from participating in competitive women’s sports.
  • Some scientists maintain that trans women and girls have no “biological advantage” over cisgender girls and women.
  • A book on the topic that reviewed evidence on testosterone determined there is no direct relation between the hormone and athletic performance.

What’s the truth?

  • In contrast, trans youth who are affirmed in schools, health care and in sports have better self-confidence and relationships with their parents.
  • Smith has incorrectly warned there are risks associated with affirmation and inclusion in schools for trans kids.
  • It includes more information on clinical guidelines for the prescription of puberty blockers for the purposes of gender-affirming care.


Corinne L. Mason receives funding from SSHRC. Leah Hamilton receives funding from SSHRC.

New Data From Vector Solutions Reveals Students Benefit From Key K-12 Safety & Wellness Courses

Retrieved on: 
Thursday, February 1, 2024

TAMPA, Fla., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Today, Vector Solutions, the leading provider of training and software solutions to help schools make their operations and communities safer, smarter, and better, released new efficacy data for its courses on Youth Suicide Risk and Bullying and Cyberbullying within the K-12 Student Safety & Wellness Course Library. These courses address key issues students are facing when it comes to mental health, interpersonal relationships, and how to seek help when they or classmates are experiencing challenges.

Key Points: 
  • These courses address key issues students are facing when it comes to mental health, interpersonal relationships, and how to seek help when they or classmates are experiencing challenges.
  • In the wake of the COVID-19 pandemic, depression and anxiety both rose significantly for K-12 students.
  • Integrated surveys in the courses measured training impact while simultaneously collecting demographic information to more deeply analyze student sub-populations.
  • To learn more about Vector Solutions' K-12 Student Safety & Wellness Course Library, click here .